

Predictors of Initial Revascularization Versus Medical Therapy Alone in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome Undergoing an Invasive Strategy

Harindra C. Wijeyesundera, MD, PhD; Mandeep S. Sidhu, MD, MBA;
Maria C. Bennell, MSc, MPH; Feng Qiu, MSc; Dennis T. Ko, MD, MSc;
Merril L. Knudtson, MD; Jack V. Tu, MD, PhD; William E. Boden, MD

Background—Although an invasive strategy is a class I clinical practice guideline for non–ST-segment–elevation acute coronary syndromes, there is wide variation in the proportion of patients who undergo revascularization despite early angiography. We sought to identify the predictors of early revascularization versus medical therapy alone in patients with non–ST-segment–elevation acute coronary syndrome undergoing an invasive strategy and to assess their clinical outcomes.

Methods and Results—We assessed revascularization status by percutaneous coronary intervention or coronary artery bypass grafting within 7 days of the index angiogram in all patients with non–ST-segment–elevation acute coronary syndrome who underwent an invasive strategy in Ontario, Canada, from October 1, 2008, to October 31, 2013, with follow-up through December 31, 2014. The primary outcome was mortality. Multivariable hierarchical logistic models identified predictors of revascularization, and multivariable Cox models with treatment strategy as a 3-level time-varying covariate assessed the relationship between revascularization status and clinical outcomes. We identified 50 302 patients of whom 34 288 (68.2%) underwent revascularization (percutaneous coronary intervention: 28 011 and coronary artery bypass grafting: 6 277). There was a 2-fold variation in revascularization rates across hospitals. A higher risk presentation significantly predicted revascularization (odds ratio, 1.26; 95% confidence interval, 1.18–1.35), as did having the angiogram by an interventional cardiologist (odds ratio, 1.76; 95% confidence interval, 1.57–1.98). Revascularized patients with either percutaneous coronary intervention (hazard ratio, 0.64; 95% confidence interval, 0.60–0.69) or coronary artery bypass grafting (hazard ratio, 0.53; 95% confidence interval, 0.47–0.60) had improved survival compared with medically treated patients.

Conclusions—Although the majority of patients with non–ST-segment–elevation acute coronary syndrome who underwent an early invasive approach received revascularization, there was wide variation. Revascularization was associated with significantly improved survival. (*Circ Cardiovasc Interv.* 2016;9:e003592. DOI: 10.1161/CIRCINTERVENTIONS.115.003592.)

Key Words: acute coronary syndrome ■ angiography ■ cardiovascular disease ■ coronary angiography
■ hospitalization

Non–ST-segment–elevation acute coronary syndromes (NSTEMI-ACS) are caused by rupture of a vulnerable plaque in an epicardial coronary artery, resulting in nonocclusive obstruction to coronary blood flow with downstream myocardial ischemia and potential necrosis.^{1–4} NSTEMI-ACS

presentations are increasing in incidence and have a poor prognosis, which is in part because of patients being elderly with multiple comorbidities.¹ The optimal timing for invasive cardiac diagnostic procedures in NSTEMI-ACS has remained an important clinical challenge.

Received December 8, 2015; accepted May 25, 2016.

From the Schulich Heart Centre, Division of Cardiology, Sunnybrook Health Sciences Centre (H.C.W., M.C.B., D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (H.C.W., D.T.K., J.V.T.), University of Toronto, Ontario, Canada; Institute for Clinical Evaluative Sciences, Ontario, Canada (H.C.W., F.Q., D.T.K., J.V.T.); Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada (H.C.W.); Samuel S. Stratton VA Medical Center, Albany Medical Center, Albany Medical College, New York (M.S.S., W.E.B.); and Foothills Hospital, University of Calgary, Alberta, Canada (M.L.K.).

The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by the Institute for Clinical Evaluative Science or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information. However, the analyses, conclusions, opinions and statements expressed herein are those of the authors and not necessarily those of the Canadian Institute for Health Information.

The Data Supplement is available at <http://circinterventions.ahajournals.org/lookup/suppl/doi:10.1161/CIRCINTERVENTIONS.115.003592/-/DC1>. Correspondence to Harindra C. Wijeyesundera, MD, PhD, Schulich Heart Centre, Division of Cardiology, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, Suite A202, Toronto, Ontario M4N3M5, Canada. E-mail harindra.wijeyesundera@sunnybrook.ca

© 2016 American Heart Association, Inc.

Circ Cardiovasc Interv is available at <http://circinterventions.ahajournals.org>

DOI: 10.1161/CIRCINTERVENTIONS.115.003592

WHAT IS KNOWN

- An early invasive strategy is recommended for patients with a non-ST-segment-elevation acute coronary syndrome, based on multiple randomized controlled trials.
- However, there is wide variation in these trials in the proportion of patients treated with an early invasive strategy who received revascularization.
- We sought to understand the drivers of revascularization in patients with an early invasive strategy and the clinical consequences.

WHAT THE STUDY ADDS

- While the majority (68.2%) of non-ST-segment-elevation acute coronary syndrome patients who underwent an early invasive approach received revascularization, there was wide variation.
- Revascularization was associated with significantly improved survival compared to medical therapy.

Clinicians are faced with 2 potential initial strategies to treat patients with NSTEMI-ACS.¹ The first is an invasive strategy, in which all patients undergo coronary angiography to determine whether revascularization is necessary in addition to adjunctive pharmacotherapies including antiplatelet, anticoagulant, and disease-modifying therapies for NSTEMI-ACS.¹ The alternative is a conservative or ischemia-driven strategy, where angiography is only performed selectively after initial pharmacological stabilization, with referral based on noninvasive testing, the presence of refractory symptoms, or clinical instability.¹ On the basis of the results of multiple clinical trials,^{5–14} current practice guidelines recommend an early invasive strategy as a class I recommendation.¹ However, an early invasive strategy with coronary angiography is not synonymous with early revascularization, and indeed, there is wide variation among these trials in the proportion of patients randomized to an invasive strategy who ultimately underwent revascularization by either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). There is a paucity of data on the factors that drive the decision as to whether to revascularize in patients with NSTEMI-ACS after angiography and in the subsequent clinical consequences of this decision.

Accordingly, we sought to address this gap in knowledge by using a population-based registry of all patients with NSTEMI-ACS who undergo angiography during their index hospitalization in Ontario, Canada. Our primary objective was to identify the predictors of revascularization of patients with NSTEMI-ACS undergoing an invasive strategy. As a secondary objective, we compared the clinical outcomes of patients who were initially treated with medical therapy (MT) alone versus those who went on to revascularization.

Methods

This study was approved by the Institutional Research Ethics Board at Sunnybrook Health Sciences Center, Toronto, Canada. Under

Ontario's Personal Health Information Protection Act, the need for patient consent was waived.

Data Sources

Ontario is Canada's largest province, with >13 million residents, all of whom have universal access to physician and hospital services through a single-payer publicly-funded healthcare program, administered by the Ministry of Health and Long Term Care of Ontario. Our analyses were conducted using data from the Cardiac Care Network of Ontario, Canada (CCN). CCN includes a network of the 19 hospitals that provide advanced cardiac services in Ontario.^{15,16} CCN maintains a prospective clinical registry of all individuals who undergo cardiac angiography, PCI, or cardiac surgery in Ontario.^{15,16} The CCN Cardiac Registry contains information on patient demographics, cardiac risk factors, and comorbidities, in addition to data on preprocedural testing, such as exercise stress testing, echocardiography, and noninvasive functional stress testing, and details on coronary anatomy. The accuracy of the anatomic and clinical data in the CCN registry has been validated through random chart audits and angiographic core laboratory evaluation.^{17,18}

Data from the CCN Cardiac Registry were linked using unique encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences. The administrative databases that we used were the Canadian Institute for Health Information discharge abstract database that contains data on all hospitalizations, the National Ambulatory Care Reporting System, which has information on emergency room visits, and the Ontario Registered Persons Database, which was used to ascertain mortality.

Study Population

Our cohort consisted of all patients admitted with a NSTEMI-ACS treated using an invasive strategy with an index in-hospital angiogram from October 1, 2008, to October 31, 2013. Consistent with the definition of NSTEMI-ACS, we included both patients who were originally classified in the CCN Cardiac registry as unstable angina and those classified as non-ST-segment-elevation myocardial infarction (MI).¹ The diagnosis of NSTEMI-ACS was based on the presenting diagnosis. Inclusion criteria were a valid Ontario health card number to facilitate linkage and age >20 years. We restricted the cohort to patients with obstructive coronary disease on angiography, defined as stenosis >70% in severity in any major epicardial coronary vessel (the left anterior descending, circumflex, or right coronary artery) or >50% in the left main coronary artery, as recorded in the CCN Cardiac Registry. We excluded patients who had an emergent angiogram for ST-segment-elevation MI or NSTEMI-ACS with hemodynamic compromise. We also excluded all cases at the 19th CCN participating hospital, which only opened in mid-2013 (n=46), given the small number of cases at that site. As such, our analyses were restricted to 18 hospitals. If multiple angiograms existed for the same patient in the accrual time period, only the first angiogram was retained in the cohort.

Exposures

We categorized patients into 2 primary treatment strategies: those with (1) an initial MT strategy versus (2) an initial revascularization strategy (either PCI or CABG) within 7 days of their index angiogram. We selected 7 days as a cutoff to capture only revascularization procedures that were intended as treatment for the initial NSTEMI-ACS presentation. For each hospital, we defined the revascularization ratio as the number of patients who underwent revascularization divided by the number of patients who were managed initially with MT.

Outcomes

Our primary outcome was all-cause mortality, based on the Ontario Registered Persons Database. The secondary outcome was hospitalization for nonfatal MI, defined using a validated algorithm based on the most responsible diagnosis (using *International Classification of Disease version 10* codes I21, I22, and I25.2) in the Canadian Institute for Health Information discharge abstract database and the National Ambulatory Care Reporting System.¹⁹




Figure 1. Selection of study cohort. CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; and PCI, percutaneous coronary intervention.

Statistical Analysis

Predictors of Treatment Strategy

We used a 2-level hierarchical logistic regression model to identify predictors of revascularization during an index NSTEMI-ACS episode. These models had a random hospital effect and a nested physician random effect to account for clustering of patients within physicians and

physicians within hospitals. The physician random effect represented the physician who was performing the index angiogram. Candidate variables included patient demographics, comorbidities, and coronary anatomy. We also evaluated the impact of the type of physician who performed the index angiogram (invasive physicians who only perform angiography versus interventional physicians who also perform PCIs) and the type of hospital (diagnostic angiography-only




Figure 2. Ratio of revascularization to medical therapy among hospitals. The revascularization ratio per hospital was defined as the number of patients with non-ST-segment-elevation acute coronary syndrome undergoing either percutaneous coronary intervention/coronary artery bypass grafting divided by the number of patients undergoing medical therapy per hospital.

Table 1. Baseline Characteristics

Covariate	Total	Medical Therapy Patients	Revascularized Patients	P Value	PCI	CABG	P Value
	(N=50 302)	(N=16 014)	(N=34 288)		(N=28 011)	(N=6 277)	
Patient-level factors							
Demographics							
Age, mean±SD	66.4±12.3	69.0±11.8	65.1±12.3	<0.001	64.9±12.6	66.4±10.6	<0.001
Female sex, n (%)	16 129 (48)	7990 (45)	8139 (50)	<0.001	8624 (31)	1517 (24)	<0.001
Income quintile, n (%)*				<0.001			<0.001
1	10 322 (21)	3497 (22)	6825 (20)		5595 (20)	1230 (20)	
2	10 484 (21)	3459 (22)	7025 (21)		5760 (21)	1265 (20)	
3	9923 (20)	3083 (19)	6840 (20)		5595 (20)	1245 (20)	
4	10 198 (20)	3169 (20)	7029 (21)		5737 (21)	1292 (21)	
5	9129 (18)	2723 (17)	6406 (19)		5190 (19)	1216 (19)	
Rural, n (%)	7653 (15)	2492 (16)	5161 (15)	0.029	4195 (15)	966 (15)	0.090
Medical comorbidities, n (%)							
Renal dysfunction	2696 (5)	1309 (8)	1387 (4)	<0.001	1190 (4)	197 (3)	<0.001
Previous MI	18 865 (38)	7338 (46)	11 527 (34)	<0.001	9615 (34)	1912 (31)	<0.001
Previous CABG	5547 (11)	2670 (17)	2877 (8)	<0.001	2817 (10)	60 (1)	<0.001
Previous stroke	894 (2)	416 (3)	478 (1)	<0.001	401 (1)	77 (1)	<0.001
COPD	4722 (9)	2018 (13)	2704 (8)	<0.001	2285 (8)	419 (7)	<0.001
PVD	4719 (9)	2162 (14)	2557 (8)	<0.001	1984 (7)	573 (9)	<0.001
Malignancy	1757 (4)	718 (5)	1039 (3)	<0.001	866 (3)	173 (3)	<0.001
Charlson score (mean±SD)	0.8±1.5	1.1±1.7	0.6±1.3	<0.001	0.7±1.3	0.5±1.2	<0.001
Cardiac risk factors, n (%)							
Hyperlipidemia	33 335 (66)	11 637 (73)	21 698 (63)	<0.001	17 568 (63)	4130 (66)	<0.001
Diabetes	21 197 (42)	8072 (50)	13 125 (38)	<0.001	10 293 (37)	2832 (45)	<0.001
Hypertension	41 641 (83)	14 243 (89)	27 398 (80)	<0.001	22 145 (79)	5253 (84)	<0.001
Smoking	14 771 (29)	5070 (32)	9701 (28)	<0.001	7719 (28)	1982 (32)	<0.001
Risk of presentation, n (%)†				<0.001			<0.001
High	9616 (19)	2833 (18)	6783 (20)		5583 (20)	1200 (19)	
Intermediate	21 991 (44)	7038 (44)	14 953 (44)		12 237 (44)	2716 (43)	
Low	18 438 (37)	6042 (38)	12 396 (36)		10 095 (36)	2301 (37)	
Missing	257 (1)	101 (1)	156 (1)		96 (1)	60 (1)	
Testing, n (%)							
Exercise stress test				<0.001			<0.001
Low risk	1019 (2)	313 (2)	706 (2)		563 (2)	143 (2)	
High risk	2213 (4)	489 (3)	1724 (5)		1244 (4)	480 (8)	
Not done	47 070 (94)	15 212 (95)	31 858 (93)		26 204 (94)	5654 (90)	
Functional imaging, n (%)				<0.001			<0.001
Low risk	1437 (3)	564 (4)	873 (3)		695 (3)	178 (3)	
High risk	2283 (5)	831 (5)	1452 (4)		1140 (4)	312 (5)	
Not done	46 582 (93)	14 619 (91)	31 963 (93)		26 176 (93)	5787 (92)	
LV function, n (%)				<0.001			<0.001
≥50%	5873 (12)	2058 (13)	3815 (11)		3032 (11)	783 (13)	

(Continued)

Table 1. Continued

Covariate	Total	Medical Therapy Patients	Revascularized Patients	P Value	PCI	CABG	P Value
	(N=50 302)	(N=16 014)	(N=34 288)		(N=28 011)	(N=6 277)	
35%–49%	2939 (6)	1260 (8)	1679 (5)		1317 (5)	362 (6)	
20%–34%	1795 (4)	953 (6)	842 (3)		659 (2)	183 (3)	
<20%	445 (1)	278 (2)	167 (1)		128 (1)	39 (1)	
Not done	39 250 (78)	11 465 (72)	27 785 (81)		22 875 (82)	4910 (78)	
Coronary anatomy, n (%)							
Left main \geq 50%	5950 (12)	2418 (15)	3532 (10.)	<0.001	1292 (5)	2240 (36)	<0.001
Proximal LAD \geq 70%	15 574 (31)	5 138 (32)	10 436 (30)	<0.001	7350 (26)	3086 (49)	<0.001
Mid/distal LAD \geq 70%	25 727 (51)	9051 (57)	16 676 (49)	<0.001	12 727 (45)	3949 (63)	<0.001
Circumflex \geq 70%	27 745 (55)	9913 (62)	17 832 (52)	<0.001	13 239 (47)	4593 (73)	<0.001
RCA \geq 70%	30 341 (60)	10 559 (66)	19 782 (58)	<0.001	15 014 (54)	4768 (76)	<0.001
Interventional physician, n (%)	35 561 (71)	10 093 (63)	25 468 (74)	<0.001	20 856 (75)	4612 (74)	<0.001
Hospital type, n (%)				<0.001			<0.001
CABG, PCI, and Cath	41 767 (83)	13 096 (82)	28 671 (84)		23 302 (83)	5369 (86)	
Cath only	3846 (8)	1189 (7)	2657 (8)		2290 (8)	367 (6)	
PCI and Cath only	4689 (9)	1729 (11)	2960 (9)		2419 (9)	541 (9)	

Covariates are presented as percentages, unless otherwise stated. CABG indicates coronary artery bypass grafting; Cath, catheterization; COPD, chronic obstructive pulmonary disease; LAD, left anterior descending; LV, left ventricular; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; RCA, right coronary artery; and TIMI, Thrombolysis in Myocardial Infarction.

*Income quintile is from 1=lowest to 5=highest.

†High risk is TIMI risk 5–7; intermediate is TIMI risk 3–4, and low risk is TIMI risk 1–2.

center, stand-alone PCI center without cardiac surgery, versus centers with both on-site PCI and CABG available).

Outcomes

Unadjusted Kaplan–Meier curves were used to compare death and recurrent MI between MT and each of the revascularization modalities. We developed multivariable Cox-proportional hazard models with the therapeutic strategy treated as a time-varying covariate to model the hazard of our primary and secondary outcomes. The treatment strategy was a 3-level categorical time-varying variable (MT versus PCI versus CABG) in that all patients were initially considered nonrevascularized (MT only) until the time of revascularization, at which point they were considered to have switched to the revascularization modality received (either PCI or CABG). Such an approach mitigates the potential for immortal time/survivorship bias. We used a robust sandwich-type variance estimator to account for the clustering of patients within hospitals. Candidate variables for risk adjustment included demographics, comorbidities/disease severity, physician characteristics, and hospital factors. As a sensitivity analysis, we repeated our primary model stratified by whether the NSTEMI-ACS presentation was high versus intermediate versus low risk. The physician referring the patient for angiography entered the risk of presentation into the CCN registry based on his/her clinical assessment. Although the Thrombolysis in Myocardial Infarction (TIMI) or Global Registry of Acute Coronary Events (GRACE) risk score was provided to the physicians and highly recommended as a guide when determining the risk of presentation, it was not mandated that the actual numeric score be provided.

SAS version 9.3 (SAS Institute Inc, Cary, NC) was used for all analyses; *P* values of <0.05 were considered significant.

Results

Cohort

From October 1, 2008, to October 31, 2013, 84 941 coronary angiograms were performed for NSTEMI-ACS. After applying

exclusions as detailed in Figure 1, our final cohort consisted of 50 302 patients with NSTEMI-ACS (68% non-ST-segment-elevation MI and 32% unstable angina) with evidence of significant obstructive coronary artery disease. Of these, 34 288 (68.2%) underwent initial revascularization within 7 days of the index angiogram (28 011 by PCI and 6 277 by CABG), whereas the remaining 16 014 patients were initially treated with MT alone. The overall revascularization ratio in the province was 2.14. However, there was wide variation in the proportion of patients who underwent revascularization across the 18 participating network hospitals as seen in Figure 2, ranging from a low revascularization ratio of 1.38 to a high of 3.17.

Baseline characteristics of the overall cohort and each treatment strategy are found in Table 1. In general, patients who underwent MT alone were older, with a higher prevalence of comorbidities including renal dysfunction, previous stroke, peripheral vascular disease, respiratory disease, and previous CABG.

Predictors of Revascularization

Results of our hierarchical multivariable logistic model are found in Table 2. We found that older age was a significant predictor of MT alone (odds ratio [OR] 0.86 for revascularization for each decade increase in age; 95% confidence interval [CI], 0.84–0.87), as was the presence of comorbidities such as previous stroke, peripheral vascular disease, respiratory disease, and previous CABG. A higher risk of NSTEMI-ACS presentation based on the physician assessment was a significant predictor of receiving revascularization, with an OR of 1.26

Table 2. Patient-Level, Physician-Level, and Hospital-Level Predictors of Revascularization, With Hospital and Nested Physician Random Effect

Covariate	OR (95% CI)	P Value
Patient-level factors		
Demographics		
Age (by increasing decade of life)	0.86 (0.84–0.87)	<0.001
Male sex	1.02 (0.98–1.07)	0.35
Income quintile*		
1	Referent	...
2	1.04 (0.98–1.10)	0.23
3	1.11 (1.04–1.18)	0.001
4	1.08 (1.01–1.15)	0.021
5	1.16 (1.08–1.23)	<0.001
Rural	0.99 (0.93–1.05)	0.75
Medical comorbidities		
Renal dysfunction	0.94 (0.85–1.03)	0.19
Previous MI	0.80 (0.76–0.83)	<0.001
Previous CABG	0.73 (0.68–0.78)	<0.001
Previous stroke	0.86 (0.74–0.99)	0.038
COPD	0.83 (0.77–0.88)	<0.001
PVD	0.76 (0.71–0.81)	<0.001
Malignancy	0.96 (0.86–1.08)	0.53
Charlson score	0.94 (0.92–0.96)	<0.001
Cardiac risk factors		
Hyperlipidemia	0.92 (0.87–0.96)	<0.001
Diabetes mellitus	0.84 (0.80–0.88)	<0.001
Hypertension	0.80 (0.75–0.85)	<0.001
Smoking	1.00 (0.95–1.04)	0.90
Risk of presentation†		
Low	Referent	...
High	1.26 (1.18–1.35)	<0.001
Intermediate	1.06 (1.00–1.11)	0.040
Missing	0.84 (0.64–1.10)	0.21
Testing		
Exercise stress test		
Low risk	Referent	...
High risk	1.27 (1.06–1.52)	0.011
Not done	0.88 (0.75–1.02)	0.085
Functional imaging		
Low risk	Referent	...
High risk	1.02 (0.87–1.18)	0.84
Not done	1.08 (0.96–1.22)	0.22
LV function		

(Continued)

Table 2. Continued

Covariate	OR (95% CI)	P Value
<20%	Referent	...
≥50%	2.80 (2.26–3.46)	<0.001
35%–49%	2.37 (1.91–2.95)	<0.001
20%–34%	1.70 (1.36–2.14)	<0.001
Not done	3.39 (2.76–4.16)	<0.001
Coronary anatomy		
Left main ≥50%	0.87 (0.82–0.93)	<0.001
Proximal LAD ≥70%	1.08 (1.03–1.13)	<0.001
Mid/distal LAD ≥70%	0.76 (0.73–0.79)	<0.001
Circumflex ≥70%	0.77 (0.74–0.81)	<0.001
RCA ≥70%	0.88 (0.84–0.91)	<0.001
Interventional physician	1.75 (1.56–1.97)	<0.001
Hospital type		
CABG, PCI, and Cath	Referent	...
Cath only	1.22 (1.01–1.48)	0.036
PCI and Cath only	0.99 (0.83–1.18)	0.90

All variables listed in this table were included in the multivariable model. CABG indicates coronary artery bypass grafting; Cath, catheterization; CI, confidence interval; COPD, chronic obstructive pulmonary disease; LAD, left anterior descending, LV, left ventricular; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; RCA, right coronary artery; and TIMI, Thrombolysis in Myocardial Infarction.

*Income quintile is from 1=lowest to 5=highest.

†High risk is TIMI risk 5–7; intermediate is TIMI risk 3–4, and low risk is TIMI risk 1–2.

(95% CI, 1.18–1.35) compared with a low-risk presentation. Preserved left ventricular systolic function was also a strong predictor of revascularization (OR, 2.80; 95% CI, 2.26–3.46). In addition, because income increased, there was a higher likelihood of revascularization.

Interestingly, other than proximal left anterior descending artery disease, more severe coronary anatomy was associated with a lower likelihood of revascularization (Table 2). If the angiogram was performed by an interventional cardiologist, there was a higher odds of subsequent revascularization (OR, 1.75; 95% CI, 1.56–1.97). Counterintuitively, if the angiogram was done at a diagnostic angiogram-only center compared with a full service center with CABG back-up, there was a higher odds of revascularization (OR, 1.22; 95% CI, 1.01–1.48).

Clinical Outcomes

Follow-up was available until December 31, 2014. Unadjusted outcomes are shown in Figure 3A and 3B. During the follow-up period, 33.3% of MT patients died and 14.4% had a repeat MI. In comparison, 16.4% of PCI patients and 17.2% of CABG patients died, whereas 6.6% and 3.6% had MIs, respectively.

The fully adjusted, time-varying Cox-proportional models are found in Table 3. In comparison to MT, patients undergoing CABG (hazard ratio, 0.53; 95% CI, 0.47–0.60) or PCI




Figure 3. A, Kaplan–Meier curve for mortality. **B,** Kaplan–Meier curve for readmissions for myocardial infarction. CABG indicates coronary artery bypass grafting; Med, medical therapy; and PCI, percutaneous coronary intervention.

(hazard ratio, 0.64; 95% CI, 0.60–0.69) had improved survival. Similar results were seen for MI (Table 3; Table I in the Data Supplement), with an hazard ratio of 0.27 (95% CI, 0.23–0.32) and 0.54 (95% CI, 0.46–0.63) for CABG and PCI, respectively.

When stratified by the risk of presentation, patients undergoing PCI or CABG had improved survival and subsequent MI rates compared with MT patients, irrespective of the risk of presentation (Table II in the Data Supplement).

Discussion

In this population-based evaluation of patients with NSTEMI-ACS undergoing an invasive strategy, we found wide variation across hospitals in terms of the rate of revascularization. Patients with a higher risk of presentation based on the physician assessment were more likely to be revascularized. In addition, we also found that both physician and hospital factors were important

drivers in the decision as to whether or not to revascularize initially. In comparison to patients on MT alone, those who underwent revascularization had significantly improved outcomes.

Table 3. Adjusted Predictors of Death and Readmission for MI*

Covariate	Death		Readmission for MI	
	HR (95% CI)	P Value	HR (95% CI)	P Value
Medical therapy	Referent	...	Referent	...
CABG	0.53 (0.47–0.60)	<0.001	0.27 (0.23–0.32)	<0.001
PCI	0.64 (0.60–0.69)	<0.001	0.54 (0.46–0.63)	<0.001

CABG indicates coronary artery bypass grafting; CI, confidence interval; HR, hazard ratio; MI, myocardial infarction; and PCI, percutaneous coronary intervention.

*Time varying for treatment. This model was adjusted for all variables listed in Table 2 (age, gender, income, rural status, medical comorbidities, cardiac risk factors, risk presentation, noninvasive testing, coronary anatomy, physician type, and hospital type).

Previous observational studies have found wide variation in the proportion of patients who undergo early angiography during a NSTEMI-ACS admission.^{20–22} Meta-analyses of randomized trials comparing an invasive versus ischemia-driven strategy in NSTEMI-ACS have generally found early angiography to be superior.^{11–13} However, these conclusions are balanced against an early hazard associated with invasive angiography, with benefits primarily restricted to higher risk patients, with more extensive evidence of ischemia. These trials have led to the guideline recommendation for an invasive strategy in patients presenting with NSTEMI-ACS.

Our study focused on the decision of whether to revascularize patients with NSTEMI-ACS already undergoing an initial invasive strategy. In the randomized trials comparing an invasive versus ischemia-driven strategy within the group randomized to an invasive strategy, there has been a striking variation in the proportion of patients who are revascularized, ranging from 44% to 78%.¹¹ A potential explanation for this might be the inclusion of patients in previous clinical trials who did not have obstructive coronary disease, despite the presentation with an acute chest pain syndrome. To mitigate against this issue in our study, we only included patients with obstructive coronary occlusions at the time of angiography.

We found that approximately two thirds of NSTEMI-ACS patients with obstructive coronary disease who underwent early angiography were ultimately revascularized. There was nonetheless wide variation across hospitals. Patients in whom the physician-assessed risk of presentation was higher were more likely to undergo revascularization. However, in counterdistinction to the physician-estimated risk, we observed an apparent paradox whereby patients with greater comorbidity were less likely to undergo revascularization.²³ A potential explanation is that although it was highly recommended that the physician assessment of risk was based on the TIMI/GRACE score, the score itself was not recorded; therefore, physicians maybe overestimating the risk of their patients based on their clinical assessment. Moreover, we found that the impact of coronary anatomy on the decision to revascularize was surprisingly modest. This suggests that physicians place greater weight on comorbidities and the associated downstream risks and their impacts on safety, as compared with potential mortality benefits when making decisions on revascularization. This is despite the contemporary nature of our study, reflecting modern revascularization practice with smaller sheath sizes, radial access, increasing second- and third-generation drug-eluting stent penetration, and safer periprocedural pharmacotherapy. Importantly, we also demonstrated an important improvement in outcomes associated with revascularization, which was independent of the estimated risk of the NSTEMI-ACS presentation.

Our study must be interpreted in the context of several limitations that merit discussion. First, there were substantial differences in baseline characteristics between groups, specifically with regard to the greater burden of comorbidities in patients treated medically. As such, despite the use of statistical techniques to account for these baseline differences, we cannot eliminate the presence of residual confounding that may account for some of our observations, in particular

contributing to the differences in clinical outcomes between groups. Second, our method of classification into either MT or revascularization is at risk for immortal time bias. We have attempted to mitigate this issue through the use of time-dependent covariates. Nonetheless, this potential bias cannot be discounted. Finally, given the observational nature of our study design, our study is hypothesis generating and should not be interpreted as confirming causality.

In conclusion, in this contemporary population-level evaluation of patients with NSTEMI-ACS undergoing an invasive strategy, we found substantial practice variation in the use of revascularization, with patients undergoing revascularization having improved outcomes.

Sources of Funding

Dr Wijesundera had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. The authors acknowledge that the clinical registry data used in this publication are from the Cardiac Care Network of Ontario and its participating hospitals. The Cardiac Care Network of Ontario is dedicated to improving the quality, efficiency, access, and equity of adult cardiovascular services in Ontario, Canada. The Cardiac Care Network of Ontario is funded by the Ministry of Health and Long-Term Care. This study was supported by the Institute for Clinical Evaluative Science, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The analyses for this study were funded in part by operating funds from Canadian Institute of Health Research, Schulich Heart Center, and the Sunnybrook Research Institute. Dr Wijesundera is supported by a Distinguished Clinical Scientist Award from the Heart and Stroke Foundation of Canada. Dr Ko is supported by a Clinician Scientist Phase II personnel award from the Heart and Stroke Foundation, Ontario Provincial Office. Dr Tu is supported by a Tier 1 Canada Research Chair award and an Eaton Scholar award.

Disclosures

None.

References

1. Amsterdam EA, Wenger NK, Brindis RG, Casey JDE, Ganiats TG, Holmes JDR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;64:e139–e228.
2. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Jneid H, Ettinger SM, Ganiats TG, Philippides GJ, Jacobs AK, Halperin JL, Albert NM, Creager MA, DeMets D, Guyton RA, Kushner FG, Ohman EM, Stevenson W, Yancy CW. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;61:e179–e347.
3. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction): developed in collaboration with the American College

- of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol*. 2007;116:e148–e304.
4. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Pearle DL, Sloan MA, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2008;51:210–247.
 5. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and fast revascularisation during instability in coronary artery disease investigators. *Lancet*. 1999;354:708–715.
 6. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, Wexler LF, Kleiger RE, Pepine CJ, Ferry DR, Chow BK, Lavori PW. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. *N Engl J Med*. 1998;338:1785–1792. doi: 10.1056/NEJM199806183382501.
 7. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy)—Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med*. 2001;344:1879–1887. doi: 10.1056/NEJM200106213442501.
 8. de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, Michels HR, Sanders GT, Tijssen JG, Verheugt FW; Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus selectively invasive management for acute coronary syndromes. *N Engl J Med*. 2005;353:1095–1104. doi: 10.1056/NEJMoa044259.
 9. Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, Lagerqvist B, Wallentin L; FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. *J Am Coll Cardiol*. 2010;55:2435–2445. doi: 10.1016/j.jacc.2010.03.007.
 10. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, Wheatley DJ, Pocock SJ; Randomized Intervention Trial of Unstable Angina Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. *Lancet*. 2002;360:743–751.
 11. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. *JAMA*. 2005;293:2908–2917. doi: 10.1001/jama.293.23.2908.
 12. Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong YH, Kozinski M, Engström T, Di Pasquale G, Kochman W, Ardissino D, Kedhi E, Stone GW, Kubica J. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. *Ann Intern Med*. 2013;158:261–270. doi: 10.7326/0003-4819-158-4-201302190-00006.
 13. O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. *JAMA*. 2008;300:71–80. doi: 10.1001/jama.300.1.71.
 14. O'Donoghue ML, Vaidya A, Afsal R, Alfreðsson J, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Windhausen F, Sabatine MS. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. *J Am Coll Cardiol*. 2012;60:106–111. doi: 10.1016/j.jacc.2012.02.059.
 15. Cardiac Care Network of Ontario. http://www.ccn.on.ca/ccn_public/FormsHome/HomePage.aspx. Accessed June 28, 2016.
 16. Cardiac Care Network (CCN) Annual Report 2010/2011. http://www.ccn.on.ca/ccn_public/FormsPublication/annual_reports.aspx. Published 2011.
 17. Tu JV, Ko DT, Guo H, Richards JA, Walton N, Natarajan MK, Wijesundera HC, So D, Latter DA, Feindel CM, Kingsbury K, Cohen EA; Cardiac Care Network of Ontario's Variations in Revascularization Practice in Ontario Working Group. Determinants of variations in coronary revascularization practices. *CMAJ*. 2012;184:179–186. doi: 10.1503/cmaj.111072.
 18. Schwalm JD, Wijesundera HC, Tu JV, Guo H, Kingsbury KJ, Natarajan MK. Influence of coronary anatomy and SYNTAX Score on the variations in revascularization strategies for patients with multivessel disease. *Can J Cardiol*. 2014;30:1155–1161. doi: 10.1016/j.cjca.2014.04.006.
 19. Ko DT, Newman AM, Alter DA, Austin PC, Chiu M, Cox JL, Goodman SG, Tu JV; Canadian Cardiovascular Outcomes Research Team. Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. *Can J Cardiol*. 2010;26:129–134.
 20. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Saucedo JF, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM, Investigators C. Utilization of early invasive management strategies for high-risk patients with non-st-segment elevation acute coronary syndromes: results from the crusade quality improvement initiative. *JAMA*. 2004;292:2096–2104.
 21. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J*. 2002;23:1177–1189.
 22. Yusuf S, Flather M, Pogue J, Hunt D, Varigos J, Piegas L, Avezum A, Anderson J, Keltai M, Budaj A, Fox K, Ceremuzynski L. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. *Lancet*. 1998;352:507–514.
 23. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. *JAMA*. 2004;291:1864–1870. doi: 10.1001/jama.291.15.1864.

Predictors of Initial Revascularization Versus Medical Therapy Alone in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome Undergoing an Invasive Strategy

Harindra C. Wijeyesundera, Mandeep S. Sidhu, Maria C. Bennell, Feng Qiu, Dennis T. Ko, Merrill L. Knudtson, Jack V. Tu and William E. Boden

Circ Cardiovasc Interv. 2016;9:

doi: 10.1161/CIRCINTERVENTIONS.115.003592

Circulation: Cardiovascular Interventions is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2016 American Heart Association, Inc. All rights reserved.

Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circinterventions.ahajournals.org/content/9/7/e003592>

Data Supplement (unedited) at:

<http://circinterventions.ahajournals.org/content/suppl/2016/07/14/CIRCINTERVENTIONS.115.003592.DC1>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation: Cardiovascular Interventions* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation: Cardiovascular Interventions* is online at:
<http://circinterventions.ahajournals.org/subscriptions/>

SUPPLEMENTAL MATERIAL

Supplemental Table 1. Adjusted predictors of death and readmission for MI, fully adjusted model*

Covariate	Death		Readmission for MI	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Medical therapy	referent		referent	
CABG	0.53 (0.47-0.60)	<0.001	0.27 (0.23-0.32)	<0.001
PCI	0.64 (0.60-0.69)	<0.001	0.54 (0.46-0.63)	<0.001
Patient-level factors				
Demographics				
Age	1.06 (1.06-1.06)	<0.001	1.05 (1.05-1.06)	<0.001
Male gender	0.95 (0.91-0.99)	0.013	0.87 (0.83-0.91)	<0.001
Income quintile†				
1	referent		referent	
2	0.91 (0.86-0.98)	0.003	0.93 (0.86-1.00)	0.059
3	0.89 (0.84-0.94)	<0.001	0.85 (0.79-0.93)	<0.001
4	0.90 (0.85-0.96)	<0.001	0.88 (0.78-0.99)	0.037
5	0.85 (0.79-0.91)	<0.001	0.80 (0.73-0.87)	<0.001
Rural	1.02 (0.94-1.10)	0.701	0.91 (0.82-1.01)	0.064
Medical comorbidities				
Renal dysfunction	1.39 (1.26-1.52)	<0.001	1.38 (1.23-1.56)	<0.001
Previous MI	1.04 (1.00-1.09)	0.041	1.21 (1.11-1.31)	<0.001
Previous CABG	0.85 (0.79-0.90)	<0.001	0.87 (0.79-0.95)	0.003

Previous stroke	1.08 (0.96- 1.21)	0.188	1.06 (0.91-1.24)	0.464
COPD	1.49 (1.41-1.58)	<0.001	1.36 (1.26-1.46)	<0.001
PVD	1.50 (1.43 -1.57)	<0.001	1.53 (1.40-1.66)	<0.001
Malignancy	1.12 (1.00 -1.26)	0.042	1.00 (0.87-1.15)	0.997
Charlson score	1.16 (1.14-1.19)	<0.001	1.17 (1.13-1.21)	<0.001

Cardiac risk factors

Hyperlipidemia	0.88 (0.82-0.94)	<0.001	0.97 (0.90-1.05)	0.496
Diabetes	1.33 (1.28-1.38)	<0.001	1.44 (1.34-1.56)	<0.001
Hypertension	1.29 (1.16-1.43)	<0.001	1.30 (1.15-1.47)	<0.001
Smoking	1.07 (1.01-1.12)	0.012	1.03 (0.96-1.10)	0.455

Risk of presentation‡

Low	referent		referent	
High	1.39 (1.30-1.49)	<0.001	1.44 (1.21-1.70)	<0.001
Intermediate	1.20 (1.13-1.26)	<0.001	1.17 (1.02-1.34)	0.025
Missing	1.22 (0.80-1.86)	0.354	1.06 (0.86-1.30)	0.599

Testing

Exercise stress test

Low risk	referent		referent	
High risk	0.76 (0.59-0.98)	0.031	0.57 (0.40-0.82)	0.002
Not done	1.25 (0.97-1.61)	0.091	1.33 (1.06-1.68)	0.015

Functional imaging

Low risk	referent		referent	
High risk	0.93 (0.78 -1.11)	0.432	0.91 (0.69-1.21)	0.518

Not done	1.04 (0.87 -1.25)	0.681	1.05 (0.84-1.30)	0.672
LV function				
<20%	referent		referent	
≥50%	0.43 (0.38-0.47)	<0.001	0.53 (0.44-0.64)	<0.001
35%-49%	0.54 (0.46-0.62)	<0.001	0.58 (0.49-0.69)	<0.001
20%-34%	0.72 (0.64-0.82)	<0.001	0.71 (0.57-0.89)	0.003
Not done	0.41 (0.36-0.46)	<0.001	0.55 (0.44-0.67)	<0.001
Coronary anatomy				
Left main ≥ 50%	1.41 (1.31-1.53)	<0.001	1.44 (1.27-1.64)	<0.001
Proximal LAD ≥ 70%	1.15 (1.05-1.24)	<0.001	1.18 (1.10-1.27)	<0.001
Mid/Distal LAD ≥ 70%	1.06 (1.02-1.11)	0.003	1.14 (1.07-1.21)	<0.001
Circumflex ≥ 70%	1.19 (1.15-1.24)	<0.001	1.22 (1.16-1.28)	<0.001
RCA ≥ 70%	1.26 (1.21-1.32)	<0.001	1.30 (1.22-1.39)	<0.001
Interventional physician	1.04 (0.99-1.09)	0.130	1.03 (0.96-1.11)	0.407
Hospital type				
CABG, PCI and Cath	referent		referent	
Cath only	1.05 (0.97-1.13)	0.207	0.77 (0.68-0.88)	<0.001
PCI and Cath only	1.15 (1.07-1.25)	<0.001	1.25 (1.14-1.36)	<0.001

*Time-varying for treatment.

† Income quintile is from 1 = lowest to 5 = highest.

‡ High risk is TIMI risk 5-7; intermediate is TIMI risk 3-4 and low risk is TIMI risk 1-2.

CABG= coronary artery bypass grafting, Cath = catheterization, CI = confidence interval, COPD = chronic obstructive pulmonary disease, HR = hazard ratio, LAD = left anterior descending, LV = left

ventricular, MI = myocardial infarction, PCI = percutaneous coronary intervention, PVD = peripheral vascular disease, RCA = right coronary artery.

Supplemental Table 2: Relationship between risk of presentation and health outcomes, fully adjusted model

Risk of presentation	Death	MI
	(HR and 95% CI)	(HR and 95% CI)
High		
Medical therapy	referent	referent
PCI	0.69 (0.62-0.76)	0.60 (0.51-0.70)
CABG	0.56 (0.48-0.67)	0.34 (0.26-0.44)
Intermediate		
Medical therapy	referent	referent
PCI	0.61 (0.56-0.67)	0.51 (0.43-0.61)
CABG	0.50 (0.44-0.58)	0.22 (0.18-0.27)
Low		
Medical therapy	referent	referent
PCI	0.63 (0.54-0.74)	0.53 (0.40-0.70)
CABG	0.53 (0.43-0.65)	0.31 (0.22-0.44)

CABG= coronary artery bypass grafting, CI = confidence interval, HR = hazard ratio, PCI = percutaneous coronary intervention.